Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational ...

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

In the 176-week study run over three years – which underpinned tirzepatide's approval for obesity last year – once-weekly injections ... type 2 diabetes and as Zepbound for obesity ...

We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at ...

As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...

The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...